Not Nvidia. Not Broadcom. But This Semiconductor Stock Is Set to Grow Faster Than Any Other Major AI Chipmaker Through the End of the Decade.

Marvell Technology is forecast to grow revenue 45% in the current fiscal year and 50% next year, with management expecting its custom AI-chip business to more than double in fiscal 2028 and accelerate further in fiscal 2029. Potential catalysts include Microsoft’s reported 300,000-chip Maia 300 order in 2027 and an expanded Alphabet agreement tied to up to $120 billion of revenue targets through fiscal 2033. The stock trades at a forward P/E of 53, supported by consensus EPS expectations of $4.20 this year, $6.72 next year, and $10.28 in 2029.

Analysis

MRVL’s upside is less about AI-capex direction than whether it can convert design wins into high-margin, recurring production revenue without becoming a low-return engineering subcontractor. The key underwriting variable is XPU gross margin and NRE recovery: hyperscaler ASIC programs can produce sharp revenue ramps but carry concentrated customer leverage, aggressive pricing, and abrupt platform-transition risk. Alphabet’s warrant structure is particularly important; revenue-linked equity issuance can transfer a meaningful portion of program economics back to the customer and dilute per-share upside precisely as reported revenue accelerates.

Custom silicon is more likely to segment workloads than broadly displace NVDA. Inference and stable, high-volume internal workloads favor ASICs, while training and rapidly changing models retain a premium for NVDA’s software ecosystem; the second-order beneficiary is AVGO, whose scale and packaging/networking breadth make it the benchmark competitor for each incremental hyperscaler ASIC program. MRVL therefore needs attach-content growth in optics, interconnect, and memory connectivity—not merely accelerator volume—to defend margins and justify a premium multiple.

Near term, the stock is vulnerable to a "design-win-to-revenue" gap: press reports on customer unit plans are not equivalent to binding purchase commitments, qualified yields, or wafer allocation. Over the next 1-3 months, the decisive catalysts are disclosed backlog, production timing, customer concentration, warrant dilution, and gross-margin guidance; a revenue beat without upward EPS/GM revision should be treated as low quality. Over 6-18 months, a successful second hyperscaler ramp would de-risk the platform, but any schedule slip or a customer choosing AVGO/internal design would compress the multiple disproportionately given the embedded acceleration assumptions.

Key Decisions for Investors

• Do not chase MRVL on design-win headlines. Initiate a 1-3 month long only after earnings show both XPU revenue/backlog visibility and consolidated gross-margin expansion; size modestly because a single customer schedule change can impair annual estimates. Thesis is falsified by flat-to-down gross-margin guidance, delayed production ramps, or material incremental warrant dilution.
• Express relative custom-silicon exposure as long AVGO / short MRVL in equal dollar amounts into MRVL earnings if MRVL rallies materially without a quantified backlog or margin bridge. AVGO has broader customer and product diversification, while MRVL bears higher execution and concentration risk; cover the short if MRVL discloses a second large production program with accretive margin guidance.
• For existing MRVL longs, buy a 3-6 month downside put spread around the next earnings report rather than selling core exposure outright. The asymmetric risk is guidance reset rather than a modest quarterly miss; reassess if management confirms customer purchase commitments, wafer supply, and economics that support fiscal-2029 EPS rather than only revenue targets.
• Monitor MSFT and GOOGL capex commentary, internal accelerator utilization, and supplier references for networking/optics content. A sustained rise in custom-ASIC deployment is bullish for MRVL and AVGO, but a capex pause or evidence that accelerator attach is being internally integrated would be the earliest signal to reduce MRVL exposure.